New head of research at Astellas Gene Therapies: "Choosing the right indications is extra important"
Morten Søgaard is leaving Pfizer to join Astellas, where he will be in charge of 100 employees. Going from one of the world largest pharmaceutical firms to a considerably smaller one will be a challenge, he says.
by ulrich quistgaard, translated by daniel pedersen
Morten Søgaard is packing up shop in New York, where he has spent the past 12 years at pharmaceutical giant Pfizer. He’s now replacing the East Coast with the West Coast, as he joins the San Francisco-based development department of Japanese Astellas Gene Therapies.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
Get full access for you and your coworkers
Start a free company trial todayRelated articles
Pfizer to acquire migraine firm for over USD 11bn
For subscribers
Danish Medicines Council rejects Novartis breast cancer drug
For subscribers
